DFX Intelligence
Private Equity Intelligence
Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.
The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.
Firms / A•••• M••••••••• L••
A•••• M••••••••• L••
Venture firm with private equity activity · probableLower middle marketAlpharetta, GAa••••.comSEC registered investment adviser
A•••• is a multi-strategy investment firm specializing in healthcare. Our mission is to unite our industry expertise and capital with entrepreneurs and management teams to deliver successful results and improve the lives of patients.
Classification
- Class
- Venture firm with private equity activityprobable, confidence 70%
- Basis
- R1c: the venture graph classifies the same adviser CORPORATE_VENTURE
- Size band
- Lower middle marketdefined by: proxy: $0.57bn Private Equity Fund GAV on the Form ADV filed 2024-10-25
Classification history (2)
- Sep 15, 2026Venture firm with private equity activity (probable, 70%, cls-pe-2)R1c: the venture graph classifies the same adviser CORPORATE_VENTURE
- Sep 13, 2026Candidate (candidate, 40%, cls-pe-1)R7: admitted on 3 Private Equity Fund(s) among 8 vehicles; no rule fired
Regulatory footprint (Form ADV)
- Adviser type
- registered investment adviser
- Form ADV filings
- Dec 16, 2020 to Oct 25, 2024
- RAUM
- $861Mregulatory assets under management of the adviser; not dry powder, not a fund size
- PE funds, latest filing
- 3
- PE fund GAV, latest filing
- $574Mreported gross assets (Form ADV), not fund size
- All private fund GAV
- $861Mevery private fund type, latest filing
- 2024 PE fund GAV
- $574Msum over funds typed Private Equity Fund with a 2024 or later as-of date
- PE share of funds, lifetime
- 38%
- Fund type mix
- filed 2024-10-25, latest gav Hedge Fund $196M, Private Equity Fund $574M, Venture Capital Fund $91.7M, latest counts Hedge Fund 2, Private Equity Fund 3, Venture Capital Fund 1, lifetime distinct Hedge Fund 4, Private Equity Fund 3, Venture Capital Fund 1
- Employees
- 17
- Headquarters
- Alpharetta, GA
- Office address
- 100 NORTH MAIN STREET, SUITE 301, Alpharetta, GA, 30009
- Business phone
- 646-844-0030
Stated criteria beside observed behaviour
34 observed deals
Stated by the firm
- Sectors
- healthcare, life sciences, transportation logistics
- Geography
- United States, Global, Europe
- Revenue
- not stated or not yet read
- EBITDA
- not stated or not yet read
- Enterprise value
- not stated or not yet read
- Equity check
- from $40.0M
- Control
- not stated or not yet read
- Thesis
- A•••• Healthcare Capital, our private equity strategy, invests in commercial-stage healthcare companies across therapeutics, medical products, and services — providing growth capital and operational partnership to companies serving patients, physicians, and life science customers in the U.S. and globally.
Observed from deals on record
- roles
- unknown 34
- period
- to 2026-01-01, from 2015-01-01, undated holdings 3, dated observations 31
- window
- last unknown, first unknown
- control
- unknown 34
- companies
- 34
- geography
- count 4, share 0.118, value CA, count 1, share 0.029, value NY
- investments
- 34
- seller kinds
- transactions
- 0
- cadence by year
- platform add on
- add ons 0, platforms 0, add ons per platform unknown
- sector known for
- 15
- disclosed value usd
- n 0
- sector distribution
- count 10, share 0.294, value life sciences, examples Ribon Therapeutics, Immunocore, EpiBiologics, Inc., Alveus Therapeutics, count 2, share 0.059, value healthcare services, examples Ellie Diagnostics, Arch Oncology, count 2, share 0.059, value industrial manufacturing, examples AtomVie, Xcell Biosciences, Inc., count 1, share 0.029, value healthcare it, examples myTomorrows
- holding period years
- n 0
- repeat counterparties
- subsector distribution
- count 10, share 0.294, value life sciences, examples Ribon Therapeutics, Immunocore, EpiBiologics, Inc., Alveus Therapeutics, count 2, share 0.059, value miscellaneous manufacturing, examples AtomVie, Xcell Biosciences, Inc., count 1, share 0.029, value veterinary, examples Ellie Diagnostics, count 1, share 0.029, value healthcare it, examples myTomorrows, count 1, share 0.029, value outpatient specialty clinics, examples Arch Oncology
34 companies on the graph (0 transactions); most in life sciences (10); observed 2015 to 2026
Funds
4 on record
| Fund | Vehicle | Vintage | Reported gross assets (Form ADV), not fund size | GAV by year | Form D sold | Lifecycle |
|---|---|---|---|---|---|---|
| A••••• A•• P•••••••• L•• ADV: Private Equity Fund | buyout or unlabelled | 2024 first reported on Form ADV | $14.5M as of Oct 25, 2024 | no Form D | Unknown | |
| A•••• H••••••••• C•••••• F••• I•• L••• ADV: Private Equity Fund | buyout or unlabelled | 2023 first reported on Form ADV | $286M as of Oct 25, 2024 | no Form D | Early deployment | |
| A•••• B••••••••• C••••••• L••• ADV: Venture Capital Fund | buyout or unlabelled | 2022 first reported on Form ADV | $91.7M as of Oct 25, 2024 | no Form D | Early deployment | |
| A•••• H••••••••• C••••••• L••• ADV: Private Equity Fund | buyout or unlabelled | unknown | $273M as of Oct 25, 2024 | no Form D | Active deployment |
Team
4 current, 1 former
Managing partner (1)
- B••••• N•• V••••••••• · Partner, Managing Member · since Jun 1, 2020 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
Partner (2)
- J•••• M•••••• F•••••• · Partner, Member · since Jun 1, 2020 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
- T••••• R•••••• V••••••••• · Partner, Member · since Jun 1, 2020 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
Platform (1)
- A••••• A•••• R••••• · Chief Compliance Officer And Chief Financial Officer · since Jul 1, 2023 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
1 former (kept with end dates)
- J•••• Z••••• · Chief Compliance Officer, Chief Financial Officer · Mar 1, 2021 to Jul 21, 2023 Inference
Portfolio
34 relationships, 0 platforms, 0 add-ons
Transactions
0 on record
No transaction naming this firm has been collected yet. The deal tape is read from SEC filings and cited announcements.
Placement agents, lenders, advisers and co-investors
2 relationships
Placement agents (2)
- E•••• P••••••• 1 shared · one time · last Jan 1, 2022
- U•• S••••••••• L•• 1 shared · one time · last Jan 1, 2023
LP commitments
0 disclosed
No LP commitment collected yet. An LP edge needs a public disclosure with a quote, such as a pension plan’s report or an announcement naming the LP.
Events
7 most recent
- Sep 16, 2026E••••••••• Closes $107M Series B
- Sep 16, 2026C••••••••• Secures $120 Million Investment
- Sep 16, 2026J••••• T••••••••• and Amplitude H••••••••• Acquisition Corporation Announce Merger
- Jun 6, 2024ANI P••••••••• to Further Expand Rare Disease Business through Acquisition of Alimera Sciences
- Jan 1, 2022Amneal Acquires S••• T•••••••••’ Baclofen Franchise
- Dec 12, 2021S••• T••••••••• Announces FDA Approval of LYVISPAH™ (baclofen) Oral Granules and the Divesture of its Plasma-derived Hyperimmune Portfolio
- Dec 16, 2020A•••• M••••••••• L•• first filed Form ADV in the extract (IA)
Across the graphs
A•••• M••••••••• L•• is the same institution as 3 records in Venture Capital, Independent Sponsors and RIA and Wealth.
Venture Capital1Independent Sponsors1RIA and Wealth1
Which record it is in each graph, what it is called there, and what the two were joined on. The Data Factory holds all nine graphs and the identity layer between them.
Checking your plan…